Phaseline

Companies › Neuraptive Therapeutics

Neuraptive Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NTX-001 (PEG-Fusion)
Polyethylene glycol (PEG)-based nerve fusion product applied topically to enhance peripher
–Phase 3Peripheral Nerve Injury Upper Limb; Peripheral Nerve InjuriesMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06616025NTX-001 (PEG-Fusion)Phase 3Peripheral Nerve Injury Upper LimbOtherMar 2027
NCT04789044NTX-001 (PEG-Fusion)Phase 2Peripheral Nerve InjuriesOtherOct 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Primus Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.